AC-201 vs Lomedeucitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
AC-201
Developed by Accro Bioscience Limited and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Lomedeucitinib
Developed by Beeline Medicines under a licence from Bristol-Myers Squibb
NCT05730725 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
Reported efficacy
Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)
Result source: NCT05730725
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AC-201 | Lomedeucitinib |
|---|---|---|
| PASI 75 | —Not reported | 63% vs 3.6%+59.4 vs placeboNCT0573072517 other results
|
| PASI 90 | —Not reported | 40.7% vs 3.6%+37.1 vs placeboNCT0573072517 other results
|
| PASI 100 | —Not reported | 3.7% vs 0%+3.7 vs placeboNCT0573072517 other results
|
| sPGA 0/1 | —Not reported | 55.6% vs 3.6%+52 vs placeboNCT057307252 other results
|
| DLQI, change | —Not reported | —Not reported |
PASI 75
- AC-201
- —Not reported
- Lomedeucitinib
- 63% vs 3.6%+59.4 vs placeboNCT05730725
17 other results
- 80.8% vs 3.6% NCT05730725
- 47.8% vs 3.6% NCT05730725
- 72% vs 4.2% NCT05730725
- 57.7% vs 4% NCT05730725
- 30.8% vs 3.6% NCT05730725
- 4% vs 0% NCT05730725
- 3.8% vs 0% NCT05730725
- 80.8% vs 4.2% NCT05730725
- 66.7% vs 4% NCT05730725
- 33.3% vs 3.6% NCT05730725
- 11.5% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 54.5% vs 4.2% NCT05730725
- 40% vs 4% NCT05730725
- 7.4% vs 3.6% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
PASI 90
- AC-201
- —Not reported
- Lomedeucitinib
- 40.7% vs 3.6%+37.1 vs placeboNCT05730725
17 other results
- 48% vs 4.2% NCT05730725
- 30.8% vs 4% NCT05730725
- 7.7% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 61.5% vs 3.6% NCT05730725
- 61.5% vs 4.2% NCT05730725
- 25.9% vs 4% NCT05730725
- 18.5% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 13% vs 3.6% NCT05730725
- 13.6% vs 4.2% NCT05730725
- 8% vs 4% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
PASI 100
- AC-201
- —Not reported
- Lomedeucitinib
- 3.7% vs 0%+3.7 vs placeboNCT05730725
17 other results
- 4% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 15.4% vs 0% NCT05730725
- 15.4% vs 0% NCT05730725
- 3.7% vs 0% NCT05730725
- 3.7% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
sPGA 0/1
- AC-201
- —Not reported
- Lomedeucitinib
- 55.6% vs 3.6%+52 vs placeboNCT05730725
2 other results
- 69.2% vs 3.6% NCT05730725
- 54.2% vs 3.6% NCT05730725
DLQI, change
- AC-201
- —Not reported
- Lomedeucitinib
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AC-201: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AC-201: 0 of 4 rows · Lomedeucitinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lomedeucitinib |
|---|---|
| Dropout rate | 7.4%BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results3.7%BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 3.7%BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Discontinued due to AEs | —BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results—BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 —BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Serious AEs | 0%BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results0%BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 3.7%BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Most frequent reported AEs | acne 14.8% (placebo 0%) covid-19 11.1% (placebo 0%) dermatitis acneiform 7.4% (placebo 0%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more resultsaphthous ulcer 11.1% (placebo 0%) folliculitis 11.1% (placebo 0%) upper respiratory tract infection 7.4% (placebo 0%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 diarrhoea 7.4% (placebo 0%) headache 7.4% (placebo 0%) influenza 7.4% (placebo 3.6%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lomedeucitinib
show 17 more results
show 2 more results
show 17 more results
show 17 more results
show 17 more results
show 14 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AC-201's landscape · Lomedeucitinib's landscape